DelMar to Present Poster of Clinical Research with VAL-083 in Patients with Chemo-Resistant Glioblastoma (“GBM”) at ASCO Annual Meeting Apr 28, 2017
Naturally Splendid Signs Exclusive Sales Agreement with Laguna Blends to Market CBD Formulated Cosmeceutical Products – Video Available on Investmentpitch.com Apr 26, 2017
DelMar Pharmaceuticals Collaborates with Duke University to Explore VAL-083 as a Front-Line Treatment for Glioblastoma Multiforme Apr 26, 2017
RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D Apr 24, 2017
DelMar Pharmaceuticals Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants Apr 22, 2017
Naturally Splendid Sends Bulk Orders to South Korea and Signs Exclusive Agreement for CBD Formulated Skincare Line Apr 20, 2017
RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA® Apr 18, 2017
DelMar Pharmaceuticals Announces Pricing Of $9,000,000 Public Offering Of Common Stock And Warrants Apr 14, 2017
Naturally Splendid Develops New HempOmega(TM) Formulations and Appoints Omega Expert to Advisory Board Apr 12, 2017
Naturally Splendid to Launch HempOmega(TM) Fortified Protein Drink at CHFA West Tradeshow Apr 9, 2017
Naturally Splendid Signs Definitive Agreement with Canature to develop HempOmega(TM) Pet Food & Treats Apr 7, 2017
DelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting Apr 6, 2017
RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma Apr 5, 2017
